Itraconazole inhaled - Pulmatrix

Drug Profile

Itraconazole inhaled - Pulmatrix

Alternative Names: Pulmazole; PUR 1900

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmatrix
  • Class Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Phase I Asthma
  • Preclinical Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 13 Mar 2018 Pulmatrix plans a phase IIa trial in Q4 2018
  • 12 Feb 2018 Phase-I clinical trials in Asthma (In volunteers) in United Kingdom (Inhalation)
  • 12 Feb 2018 Phase-I clinical trials in Asthma in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top